Pacific Biosciences of California (PACB) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Pacific Biosciences of California

NASDAQ | PACB

1.17

USD

-0.03 (-2.50%)

AT CLOSE (AS OF Apr 17, 2025)

$348M

MARKET CAP

P/E Ratio

-1.59

EPS

$2.7

52 Week High

$1.1

52 Week Low

LIFE SCIENCES

Sector

PACB Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

PACB Technicals

Tags:

PACB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$37M
Total Revenue	$154M
Cost Of Revenue	$117M
Costof Goods And Services Sold	$117M
Operating Income	-$356M
Selling General And Administrative	$175M
Research And Development	$135M
Operating Expenses	$394M
Investment Income Net	-
Net Interest Income	-$13M
Interest Income	-
Interest Expense	$13M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$53M
Income Before Tax	-$310M
Income Tax Expense	$316K
Interest And Debt Expense	-
Net Income From Continuing Operations	-$310M
Comprehensive Income Net Of Tax	-
Ebit	-$410M
Ebitda	-$356M
Net Income	-$310M

Revenue & Profitability

Earnings Performance

PACB Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$1.3B
Total Current Assets	$496M
Cash And Cash Equivalents At Carrying Value	$55M
Cash And Short Term Investments	$55M
Inventory	$59M
Current Net Receivables	-
Total Non Current Assets	$765M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	$390M
Intangible Assets Excluding Goodwill	$390M
Goodwill	$318M
Investments	-
Long Term Investments	-
Short Term Investments	$335M
Other Current Assets	$19M
Other Non Current Assets	-
Total Liabilities	$754M
Total Current Liabilities	$66M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$10M
Total Non Current Liabilities	$688M
Capital Lease Obligations	$25M
Long Term Debt	$647M
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$672M
Other Current Liabilities	$26M
Other Non Current Liabilities	$19M
Total Shareholder Equity	$507M
Treasury Stock	-
Retained Earnings	-$2.1B
Common Stock	-
Common Stock Shares Outstanding	$288M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$206M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$41M
Capital Expenditures	$6.2M
Change In Receivables	-
Change In Inventory	-$8.3M
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	-$43M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$310M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$37M
Total Revenue	$154M
Cost Of Revenue	$117M
Costof Goods And Services Sold	$117M
Operating Income	-$356M
Selling General And Administrative	$175M
Research And Development	$135M
Operating Expenses	$394M
Investment Income Net	-
Net Interest Income	-$13M
Interest Income	-
Interest Expense	$13M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$53M
Income Before Tax	-$310M
Income Tax Expense	$316K
Interest And Debt Expense	-
Net Income From Continuing Operations	-$310M
Comprehensive Income Net Of Tax	-
Ebit	-$410M
Ebitda	-$356M
Net Income	-$310M

PACB News

PACB Profile

Pacific Biosciences of California Profile

Sector: LIFE SCIENCES

Industry: LABORATORY ANALYTICAL INSTRUMENTS

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to solve genetically complex problems. The company is headquartered in Menlo Park, California.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.00	9.68%	-	409,386,220
STSS	$0.03	20.75%	$522.68K	391,799,240
NVDA	$101.49	-2.87%	$2.48T	292,517,465
HTZ	$8.24	44.31%	$2.54B	266,908,117
FMTO	$0.02	-35.81%	$2.41M	198,396,141

Symbol	Price	Change %	Market Cap	Volume
LLY	$839.96	14.30%	$754.27B	10,853,385
PG	$170.63	2.55%	$400.10B	7,227,061
JNJ	$157.47	2.31%	$379.48B	10,981,067
ABBV	$172.99	0.76%	$306.02B	8,998,056
NVO	$58.08	-7.63%	$282.79B	32,220,629

Symbol	Price	Change %	Market Cap	Volume
MSGM	$2.75	145.54%	$8.75M	36,058,545
SXTC	$2.16	118.42%	$29.73M	51,508,885
ADGM	$1.78	92.81%	$54.65M	114,733,769
PNBK	$3.28	73.55%	$13.04M	1,511,087
RTC	$0.37	72.09%	$10.86M	187,018,434

Symbol	Price	Change %	Market Cap	Volume
JEWL	$0.00	-90.83%	$2.78M	470,134
LXEH	$6.84	-70.25%	$26.82M	1,373,607
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
MMV	$0.48	-51.02%	$11.90M	1,568,644

Quick Links

PACB $1.17 (-2.50%) Quote details